


UAB THE UNIVERSITY OF
ALABAMA AT BIRMINGHAM.

UAB IMMUNOLOGY
INSTITUTE

The University of Alabama at Birmingham



UAB HSOM Immunology Institute Annual Review – Feb 2024

<https://www.uab.edu/medicine/immunologyinstitute/>

HEERSINK SCHOOL OF MEDICINE

Annual Review 2024


An interdisciplinary research hub for faculty, researchers, trainees, clinicians, health policy experts, and educators who seek to advance the study of the immune system and its role in health and disease

Today's Presentation

- Achievements 2023
 - I. Membership and Funding
 - II. Education, Outreach and Training
 - III. External and internal engagement
 - IV. Build Research Capabilities (Infrastructure)**
 - V. Finances
- Goals 2024


FY23 Achievements

I. Membership and Funding





Growing the Institute - Staffing

New staff and (Lorenzo Thompson MD and Davide Botta PhD)
and designated Institute administrative office space



Immunology Institute Membership and Funding

- ❖ 158 faculty with 124 active researchers and 26 teaching/retired/emeritus/instructor faculty
- ❖ Faculty represent 24 Departments across 7 UAB Schools (90% in HSOM)
- ❖ 102/124 (82%) Research Intensive Faculty have current extramural funding
- ❖ 343 active grants (12/18/23) totaling \$91M in *directs only for the current 1 yr* funding period
 - ❖ These include 182 NIH grants totaling \$68.5M *in directs only for the current 1 yr* funding period
 - ❖ 75% of all member funding is from NIH
- ❖ II member grant portfolio includes 286 Pending Applications totaling \$503M (direct+indirect, all years)
 - ❖ 175 of pending applications are to NIH (\$296M total)
 - ❖ 59% of all member pending funding is from NIH



Impact of the studies conducted by II members

ICITE Report

ICite: Influence provides **Relative Citation Ratio (RCR)** values, which measure the scientific influence of each paper by field- and time-adjusting the citations it has received, and benchmarking to the median for NIH publications, the value of which is set at 1.0. Fields are defined for each article by using its co-citation network. This benchmarking process ensures that a paper with an RCR of 1.0 has received the same number of cites/years as the median NIH paper in its field, while a paper with an RCR of 2.0 has received twice as many cites/year as the median NIH-funded paper in its field. The displayed values are maximum, the mean, the SEM and the median of the papers in the group. **Weighted RCR** - is the sum of the RCRs for the articles in the group. This weights the article count by their influence relative to NIH-funded papers. A highly influential set of articles will have higher **Weighted RCR** than **Total Pubs**, while a set of articles with below average influence will have a lower **Weighted RCR** than **Total Pubs**

2018-2022 (98 faculty); 335 pubs; 170 pubs RCR/yr ≥ 1 ; mean RCR =2; weighted RCR = 713


2019-2023 (150 faculty), 386 pubs; 163 pubs RCR/yr ≥ 1 ; mean RCR =2; weighted RCR = 882

Based on these metrics, members of the II are publishing influential papers


Research Networking between HSOM II Members

Dimensions analysis

9 broad research category clusters with 2776 co-authorship links




Opportunity to increase connectivity across research categories



We now have examples of new cross-discipline studies/grant applications

FY23 Achievements

II. Support Education, Outreach, Training



Community engagement and education



In 2023, the II supported the Undergraduate Immunology Society (UIS) in engaging approximately 200 participants in learning about immunology at **McWane Science**.

UIS/II will also host a series of immunology workshops at Vestavia Hills Elementary East and **Vestavia Hills Elementary Liberty Park** in March 2024.



(Under) Graduate Education and training

156 trainees and staff are II members
Activities for Trainees managed by II

- Trainee Research in Progress
- AMC21 Scholar Program – GBS
- Program in Immunology Seminar Series
- Annual UAB II Symposium (Vaccine Day)
- Southeastern Immunology Symposium

“ I chose immunology because it allows me to delve into the unknowns of the system that protects each one of us. ”

Nathaniel Goldfeiz
Freshman Representative
Undergraduate Immunology Society




UAB IMMUNOLOGY INSTITUTE


RESEARCH IN PROGRESS

OCT. 5, 2023
3:30 - 5:00 PM
BBRB 170

NICOLE ARROYO-DIAZ
IFN- γ production by Tfh cells is required for CXCR3+ pre-memory B cell differentiation and subsequent lung-resident memory B cell responses



NICOLE ARROYO-DIAZ
PHD CANDIDATE
GBS: IMMUNOLOGY THEME




MILLIE PEREZ
PHD CANDIDATE
DEPARTMENT OF MEDICINE

JOIN US!

MILLIE PEREZ
CD151+ T Cell Frequencies as an Immunological Clock that Identifies Premature Immunological Aging in People With HIV

<https://www.uab.edu/medicine/immunologyinstitute/news-events/research-in-progress>

Program in Immunology Seminar Series



Program in Immunology Seminar Series

Building Platforms to Enhance Immunology Research at UAB

Thursday
September 28, 2023
3:30 PM
BBRB 170

Frances Lund, Ph.D.

Professor, Department of Microbiology
Director, Immunology Institute
UAB

Sponsored by UAB
Comprehensive Transplant Institute/Comprehensive Diabetes Center/O'Neal Comprehensive Cancer Center/Comprehensive Arthritis, Musculoskeletal, Bone and Autoimmunity Center/Center for AIDS Research/Clinical Immunology and Rheumatology/Microbiology/Medicine

Thursdays from 3:30 to 5:00 pm at BBRB 170
Mingle with colleagues and the speaker after the seminar!

23-24 Series: 19 External Speakers plus 8 Internal Speakers
24-25 Series: Completely booked 17 external + 9 internal

When speakers agree, the talks are posted internally for one week for viewing by those who can't attend the seminar



Symposia and Events

Annual Immunology Symposia

Annual Southeastern Immunology Symposia – BHM 2024!!

2023 Dorothy Oliver and Drucilla Russ-Jackson Vaccine Lecture and Symposium

Wednesday
Oct. 11, 2023

11 AM - 4 PM

Alys Stephens
Center

**SeXX Differences in
Vaccine Outcomes**

Keynote speaker
Sabra Klein, Ph.D.


Professor,
Molecular Microbiology
and Immunology,
Johns Hopkins University



Join us for the lecture, half-day
symposium and poster session with
cash prizes to win!

Abstract
Submission

Registration



The Eleventh SIS
Friday - Saturday
August 16 - 17
2024

#What's UP Bhm?



**AT THE
RED MOUNTAIN
THEATRE &
BIRMINGHAM
CIVIL RIGHTS
INSTITUTE**




Jenny Ting, UNC
Jason Cyster, UCSF
Dave Masopust, UMinn

AMC21 Scholar Award Program

- Started program in 2017
- Renewed program in 2023, budgeted for 6 recruits/year
- 27 students recruited to date
- 5 students graduated
- Accept 32 nominations from themes each year
- Interview ~15 students
- Extend offers to 11-12 students



New Partner!!



- II (Davide Botta) will manage (day to day) program with updated selection committee
- Need to select a new Faculty Advisor for program
- Changed distribution of funding (\$7500/yr to lab, \$2500 award to applicant at time of matriculation, \$7500 award to applicant for professional advancement)

AMC21 Scholar Program

Our first graduates!!

Gunars Osis



PhD 2022
A. Agarwal Mentor
AHA Fellowship
4 Publications
Bioinformatician ASRT

Rachel Andrews




PhD 2022
O. Kutsch Mentor
3 publications
Gov Contractor

Robert Phillips



PhD 2023
J. Day Mentor
T32 Recipient
6 publications
PDF Lieber Institute

Sam Mabry



PhD 2023
A. Galli Mentor
6 publications
PDF - Pitt


Jennifer Fisher



PhD 2023
B. Lasseigne Mentor
11 publications
Computational Biol.
CFD Corp

FY23 Achievement

III. Engagement with other External and Internal Research Units



Recruitment and Retention Investments



Paul Goepfert
ID



Nathan Erdmann
ID



J. Victor Garcia-Martinez
Micro



Support also offered: Ballesteros-Tato, Leon, Collier, Hull but all said no ☹️

Support multi-disciplinary grants

Metabolic risk factors and inflammation in PASC development (\$1M award; first II cross-disciplinary grant initiative – 26 investigators across 4 schools (HSOM, SPH, SOHP, SON)



Used this II supplement as a model for building Research Infrastructure to enhance competitive new applications

**Research Opportunity Announcement OTA-21-015I:
RECOVER PASC IMMUNOPHENOTYPING CORE LABORATORIES**

The NIH is soliciting applications in support of the goals of the Researching COVID to Enhance Recovery (RECOVER) Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Initiative and Investigator Consortium. This Research Opportunity Announcement focuses on immunophenotyping core laboratory analyses performed in biospecimens collected in the RECOVER adult and pediatric cohorts. The distribution of this research opportunity announcement is limited to sites participating in the RECOVER PASC Consortium.

UAB HEERSINK
SCHOOL OF MEDICINE

The University of Alabama at Birmingham

UAB SCHOOL OF
HEALTH PROFESSIONS

The University of Alabama at Birmingham

UAB SCHOOL OF
PUBLIC HEALTH

The University of Alabama at Birmingham

UAB IMMUNOLOGY
INSTITUTE

The University of Alabama at Birmingham

UAB INFORMATICS
INSTITUTE

The University of Alabama at Birmingham

UAB NUTRITION OBESITY
RESEARCH CENTER

The University of Alabama at Birmingham

UAB COMPREHENSIVE
DIABETES CENTER

The University of Alabama at Birmingham

UAB DIABETES
RESEARCH CENTER

The University of Alabama at Birmingham

Support multi-investigator grant applications (\$54,616,588)¹⁸

Dr. Carol Ballinger (II Admin Manager) provided all Administrative Support for II Member multidisciplinary grants


1. **T32** AI007051-46; Immunologic Diseases and Basic Immunology; Laurie Harrington, PhD (CDIB) PD/PI. \$3,003,231 total requested.
FUNDED

2. **U19** AI181105-01; Evolution and Durability of Human T and B Cell Responses; Frances Lund PhD (Micro) PD/PI. \$18,562,505 total – **NOA expected**. 14 investigators across 7 Dept/Divisions

3. **R24** AI176909-01A1; A Global Research Resource for Human Tuberculosis; Adrie Steyn PhD (Micro) PD/PI. \$5,898,112 total requested. Submitted. 6 investigators including international institution

4. **BAA-NIAID-75N93023R00002**; Identification and characterization of immunodominant B cell HLA alloepitopes in transplant patients; Frances Lund PhD (Micro) PD/PI. \$9,592,805 total requested. Submitted. 11 investigators across 7 Depts/Divisions.


THE PERFECT ACADEMIC GRANT APPLICATION
GRANTSCIENCE.COM



5. **R25** GM154342-01; Learning Immunology to Foster science Education (LIFE); Heather Bruns, PhD (Micro) PD/PI. \$1,350,000 total requested. Submitted 4 investigators across 2 schools

6. **U24** HL175764-01; Consortium Organization and Data Collaboration Center for the Human Virome Program. Elliot Lefkowitz (Micro) PD/PI. \$16,219,935 total requested. Submitted. 8 investigators across 4 institutions


Administrative and financial oversight of I-4ward



- ❖ Direct I-4ward Task Force
- ❖ Provide matching funds for single cell spatial proteomics and transcriptomics
- ❖ Provide matching support for single cell spatial informatics
- ❖ Direct the informatics working group
- ❖ HSF-GEF grant application and progress reports
- ❖ Communications and outreach to I-4ward research community

FY23 Achievements

IV. Build II Research Capabilities and Portfolio



1. Immunology Institute Pilot Project Funds (with OCCC)

Awarded 3 pilots on Jan 1, 2024 (\$50,000/yr for up to 2 years)

1. **Sunil Sudarshan (Urology) and Lyse Norian (Nutrition Science):** Oncometabolic Regulation of the Immune Response and Immunotherapy Efficacy in Kidney Cancer. *Funded as a match with OCCC for up to 2 years.*
2. **Chander Raman (Dermatology) and Lin Jin (Dermatology):** Elucidating interactive network of NKT and NK cell populations and skin resident cells in Hidradenitis suppurativa (HS) pathogenesis. *Funded 1 year.*
3. **Xu Feng (Pathology):** RANK Signaling Mechanism in the Immune System. *Funded for up to 2 years.*



2. Coordinate think tanks – II initiated multi-investigator projects

Cooperative Centers on Human Immunology




NOA expected – 8 Depts and Divisions, 6 clinical researchers, 7 basic researchers, 1 bioinformatician



Transplant&ObGyn



Transplant&Informatics



Immunol&Nephrology



Molecular&Structural Biol




Pulmonary
Immunol&ID&Transplant



Structural Biol

3. UAB Healthy Donor Cohort (with CCTS)

- ❖ Need healthy donor controls to compare to patient cohort samples
- ❖ Need healthy donor controls to troubleshoot and optimize methods
- ❖ Need healthy donor controls to study fundamental biologic processes (not disease-based)



Lorenzo Thompson Carol Ballinger Jennifer Croker

**Research Volunteers
NEEDED**

UAB HEALTHY DONOR COHORT



- Are you 18 years or older?
- Do you weigh more than 110 pounds?
- Are you in overall good health?
- Are you willing and able to donate blood samples for UAB Research?

If you answered YES:
Go to <https://redcap.link/uabhdc> or scan the QR code with your cellphone camera for more information


You will receive \$45 for the first sample provided to the study and \$30 for each subsequent sample

For questions, please contact the study coordinator at 205-659-0944

465 individuals enrolled in UAB Healthy Donor Cohort



- ❖ Age: Mean 36.8, min 18, max 80
- ❖ Sex: 26% male 74% female
- ❖ Race: 67% White, 15% Black, 12% Asian, Other 6%
- ❖ Ethnicity: 5% Hispanic/Latino



Research volunteers needed

by Jeff Hansen

UAB Reporter

Gillian Brooks of WBRC Channel 6 FOX News

2. Immunophenotyping Core (with FCSCC and OCCC)



Advanced immunophenotyping: A powerful tool for immune profiling, drug screening, and a personalized treatment approach

METHODS article


Front. Immunol., 24 March 2023
Sec. Autoimmune and Autoinflammatory Disorders:
Autoinflammatory Disorders
Volume 14 - 2023 | <https://doi.org/10.3389/fimmu.2023.1096096>

- Teresa Preglej
- Marie Brinkmann
- Günter Steiner
- Daniel Aletaha
- Lisa Göschl**
- Michael Bonelli**


Esther Zumaquero



Steffanie Sabbaj



Chris Fucile




Sagar Hanumanthu



Lorenzo Thompson



Jack Wimbish



Alex Rosenberg



Harish Pal



Davide Botta



Rob Welner



Troy Randall



Fen Zhou

Initial flow panels for human immunophenotyping

PBMC panel (29 markers): VALIDATED AND READY (Tissues and blood)

B cell panel (19 markers): VALIDATED AND READY (Tissues and blood)

T cell panel (33 markers): OPTIMIZING

Myeloid lineage panel (34 markers): TESTING BEGAN IN JANUARY


42 different immune cell subsets identified using the PBMC panel

NKT Cells	NKT cell	CD19-/CD14-/CD3+/CD56+
NK Cells	CD56bright CD16- NK Cell CD56+dim CD16+ NK Cell CD56- CD16+ NK Cell	CD19-/CD14-/CD3-/CD56bright/CD16- CD19-/CD14-/CD3-/CD56+/dim/CD16+ CD19-/CD14-/CD3-/CD56-/CD16+
CD3+ Cells	CD3+ T Cell	CD19-/CD14-/CD56-/CD3+
CD4+ Cells	CD4+ T Cell CD4 Naive T cell (Nav) CD4 Central Memory T Cell (CM) CD4 Effector Memory T Cell (EM) CD4 Effector Memory RA+ T Cell (EMRA) CD4 Anergic CD4 Senescent CD4 No-Expression CD4 Exhausted	CD19-/CD14-/CD56-/CD16-/CD3+/CD4+ CD19-/CD14-/CD56-/CD16-/CD3+/CD4+/CCR7+/CD45RA+ CD19-/CD14-/CD56-/CD16-/CD3+/CD4+/CCR7-/CD45RA+ CD19-/CD14-/CD56-/CD16-/CD3+/CD4+/CCR7-/CD45RA- CD19-/CD14-/CD56-/CD16-/CD3+/CD4+/CCR7+/CD45RA- CD19-/CD14-/CD56-/CD16-/CD3+/CD4+/PD1+/CD57+ CD19-/CD14-/CD56-/CD16-/CD3+/CD4+/PD1-/CD57+ CD19-/CD14-/CD56-/CD16-/CD3+/CD4+/PD1-/CD57- CD19-/CD14-/CD56-/CD16-/CD3+/CD4+/PD1+/CD57-
CD8+ Cells	CD8+ T Cell CD8 Naive T Cell (Nav) CD8 Central Memory T Cell (CM) CD8 Effector Memory T Cell (EM) CD8 Effector Memory RA+ T Cell (EMRA) CD8 Anergic CD8 Senescent CD8 No-Expression CD8 Exhausted	CD19-/CD14-/CD56-/CD16-/CD3+/CD8+ CD19-/CD14-/CD56-/CD16-/CD3+/CD8+/CCR7+/CD45RA+ CD19-/CD14-/CD56-/CD16-/CD3+/CD8+/CCR7-/CD45RA+ CD19-/CD14-/CD56-/CD16-/CD3+/CD8+/CCR7-/CD45RA- CD19-/CD14-/CD56-/CD16-/CD3+/CD8+/CCR7+/CD45RA- CD19-/CD14-/CD56-/CD16-/CD3+/CD8+/PD1+/CD57+ CD19-/CD14-/CD56-/CD16-/CD3+/CD8+/PD1-/CD57+ CD19-/CD14-/CD56-/CD16-/CD3+/CD8+/PD1-/CD57- CD19-/CD14-/CD56-/CD16-/CD3+/CD8+/PD1+/CD57-
B Cells	B Cell Transitional B Cell Naive B Cell Unswitched Memory B Cell Switched Memory B Cell IgG+ Switched Memory B Cells True IgM+ Memory B Cells Double Negative IgG+ Double Negative IgM+ Double Negative DoubleNegative 2 Plasmablast Plasma Cell	CD3-/CD14-/CD56-/CD19+ CD3-/CD14-/CD56-/CD19+/IgD-/CD27-/CD24+/CD38+/IgM+ CD3-/CD14-/CD56-/CD19+/IgD-/CD27-/IgM+ CD3-/CD14-/CD56-/CD19+/IgD+/o/CD27+/IgM+ CD3-/CD14-/CD56-/CD19+/IgD-/CD27+ CD3-/CD14-/CD56-/CD19+/IgD-/CD27+/IgG+ CD3-/CD14-/CD56-/CD19+/IgD-/CD27+/IgM+ CD3-/CD14-/CD56-/CD19+/IgD-/CD27- CD3-/CD14-/CD56-/CD19+/IgD-/CD27-/IgG+ CD3-/CD14-/CD56-/CD19+/IgD-/CD27-/IgM+ CD3-/CD14-/CD56-/CD19+/IgD-/CD27-/CD11c+ CD3-/CD14-/CD56-/CD19+/IgD-/CD27+/CD38+/CD24-/CD138- CD3-/CD14-/CD56-/CD19+/neg/IgD-/CD27+/CD38+/CD24-/CD138+
Monocytes	Classical Monocyte Intermediate Monocyte Non-Classical Monocyte	CD3-/CD19-/CD56-/CD8-/HLA-DR+/CD14+/CD16- CD3-/CD19-/CD56-/CD8-/HLA-DR+/CD14+/CD16+ CD3-/CD19-/CD56-/CD8-/HLA-DR+/CD14-/CD16+
DCs	DC CD1c+ Conventional DC CD141+ Conventional DC Plasmacytoid DC	CD3-/CD14-/CD16-/CD19-/CD56-/HLA-DR+ CD3-/CD14-/CD16-/CD19-/CD56-/CD11b-/HLA-DR+/CD11c+/CD141-/CD1c+ CD3-/CD14-/CD16-/CD19-/CD56-/CD11b-/HLA-DR+/CD11c+/CD1c-/CD141+ CD3-/CD14-/CD16-/CD19-/CD56-/CD11b-/HLA-DR+/CD11c-/CD123+/CD303+

Immunophenotyping Core workflow



Davide Botta



Harish Pal




Sagar Hanumanthu



Fen Zhou




Alex Rosenberg




Jack Wimbish

Panels analyzed in a templated format for large cohorts


SARS-CoV-2 specific memory B cells in Long-COVID (PASC⁺) patient blood samples (n=210 patients)




Spike-Specific SWM



Spike-Specific IgG⁺ SWM



Funded Recover/NOSI Grant



5. Immunology Institute supporting development and distribution of immunology-relevant clinical data bundles

- Rapidly obtain bundled clinical data sets that are semi-tailored for our research interests
- Can be used to determine whether potential cohort exists or to collect clinical information on an existing cohort
- Initial bundles are focused on diseases that are often treated with immune-modulating therapies

Immunology-relevant bundles

- ❖ Respiratory infection/disease
 - ❖ Acute and Long COVID
 - ❖ Viral and bacterial
- ❖ Rheumatic Disease
 - ❖ Lupus
 - ❖ RA
- ❖ Cancer Immunology
 - ❖ MM, Breast, Ovarian etc
- ❖ Transplantation
 - ❖ Kidney, lung etc




Figure 1 Applications of Big Data

Published in IEEE International Advance Computing Conference 2017

Big Data Security in Healthcare: Survey on Frameworks and Algorithms

Sudipta Chandra Soumya Ray R. T. Goswami



UAB Learning Health System (LHS) Platform


Cooperative effort with faculty and staff from COERE, Informatics Institute, RISC and CCTS



Michael J Mugavero, MD, MHS
Professor, Infectious Diseases
COERE Director




Allyson Hall, PhD
Professor, Dept of Health Services Administration
COERE Co-Director



Reid Eagleson, MEng, MS
COERE Program Manager
Embedded Scientist



Matt Wyatt, MSHI
Informatics Institute,
Director of Clinical Research Informatics



Dale Johnson, MS
Informatics Institute,
Informatics Architect



James H. Willig, MD, MSPH
Professor, Infectious Diseases
RISC Co-Director/Informatics



Alfredo L. Guzman, MEng, MSHI
RISC Information Technology Director




Greer Burkholder, MD, MSPH
Assoc Professor, Infectious Diseases,
RISC Director of Data Services





Mohit Varshney, MD
RISC Clinical Data Specialist



Urva Tul Vusqa, MBBS
RISC Clinical Data Specialist



Suneetha Thogaripally, MEng
RISC Senior Data Analyst



Clinical data bundles are reusable research data requests

Cohort definition

- The cohort can be patient- or encounter-centric
- The cohort will probably include important index dates
- Can include MRNs or de-identified data



Specification of the discrete data values needed, the level of detail needed, and how to organize that data

- The specifications can be a mix of “give me everything” and “give me aggregates for each person/encounter in my cohort”
- Aggregates can be most recent, earliest, Y/N flags, highest, lowest, etc.
- Aggregates can be date-windowed


Reusable

- Once a bundle is defined for a specific disease – COVID, RA, SLE – anybody can apply that bundle to their own cohorts.
- We have off-the-shelf groups of common comorbidities, most-ordered labs, social history, and common vital signs that anyone can include in new bundle definitions.

Examples of information in a data bundle

(n>300 variables) for long-COVID data bundle


- ❖ Patient Identifiers
- ❖ Demographics
- ❖ Diagnoses
- ❖ Co-morbidities
- ❖ Vitals
- ❖ Hospitalizations/ICU
- ❖ Microbiology labs
- ❖ CBC/Lymphocytes
- ❖ Clinical labs (ALT, CRP etc)
- ❖ Medications (Home, Hospital)



Created by Symbolon
from Noun Project

6. Investments in Research Infrastructure – Spatial proteomics and transcriptomics

Lunaphore COMET Multiplex Imaging System – single cell
Rapid hyperplex made easy –visualize up to 40 markers in a single sample in a day



Investment by: Immunology Institute, I-4ward, OCCC

Lunaphore Comet and Visiopharm Analytic Software Suite

- ❖ Antibody panels developed and validated
- ❖ Human panels
 - ❖ n=28 antibodies
 - ❖ Colon Cancer Panel (20 antibodies)
 - ❖ PDAC panel (19 antibodies)
 - ❖ Lung panel (14 antibodies)
- ❖ Mouse panels
 - ❖ N=28 antibodies
 - ❖ PDAC panel (17 antibodies)
 - ❖ Lymphoid tissue (14 antibodies)
 - ❖ Breast cancer (8 antibodies)
- ❖ Visiopharm software
 - ❖ Deep learning-based algorithms
 - ❖ Kaltura channel training videos
 - ❖ Analytic seats available
 - ❖ Azure virtual computing systems



Julie Carstens




Harish Pal



Aaron Silva-Sanchez

UAB Research Computing:
Scott Carson, David Fox,
William Warriner, John-Paul
Robinson, Jamie Witter,
Ralph Zottola

mdLN D8 post-influenza




Aaron Silva-Sanchez - Rheumatol



Interrogation of features based on any type of grouping


(e.g. responders, drug treatment, genotype etc)

Album	Channels
<input checked="" type="checkbox"/>	DAPI
<input type="checkbox"/>	Cy5
<input type="checkbox"/>	TRITC
<input type="checkbox"/>	OSTEOPONTIN - Cy5
<input type="checkbox"/>	FOXP3 - Cy5
<input type="checkbox"/>	CD31 - TRITC
<input checked="" type="checkbox"/>	CD68 - Cy5
<input type="checkbox"/>	CD56 - TRITC
<input checked="" type="checkbox"/>	CD8 - Cy5
<input checked="" type="checkbox"/>	CD4 - TRITC
<input type="checkbox"/>	aSMA - Cy5
<input type="checkbox"/>	PDL1 - TRITC
<input type="checkbox"/>	CD163 - Cy5
<input type="checkbox"/>	PD1 - TRITC
<input type="checkbox"/>	CD3 - TRITC
<input type="checkbox"/>	CD206 - Cy5
<input type="checkbox"/>	CD69 - Cy5
<input type="checkbox"/>	GranzB - TRITC
<input type="checkbox"/>	CD16 - TRITC
<input checked="" type="checkbox"/>	CD19 - Cy5
<input checked="" type="checkbox"/>	CD11b - TRITC
<input type="checkbox"/>	FAP - Cy5
<input type="checkbox"/>	Keratin17_19 - TRITC




Julie Carstens – Heme Onc

UAB tissue repository
PDAC



Visiopharm Software

- Tissue Segmentation
- Cell Segmentation
- Cell Phenotype
- Interactive TSNE



Single cell resolution spatial transcriptomics (Xenium) on the same tissue sample that is used for spatial proteomics

36


Single cell Resolution spatial transcriptomics in fresh frozen and FFPE tissue

Xenium In Situ

High-performance
in situ from the
single cell leader

[Request pricing](#)

[See performance](#)





In this breast cancer sample (Stage II-B, ER+/PR-/HER2+), Xenium identifies a previously unknown triple-positive region.

- ❖ HSF-GEF Awarded \$180,000 to Immunology Institute (Lund), I-4ward and Brain Health (Jeremy Day and Fran Lund), Flow Cytometry and Single Cell Core (Troy Randall), Biologic Data Sciences Core (Liz Worthey)
- ❖ Matching Support: \$629,500
 - ❖ HSOM, SOE
 - ❖ UAB Centers and Institutes (n=14)
 - ❖ HSOM Departments and Divisions (n=11)
 - ❖ HSOM Strategic Research Groups
- ❖ full time bioinformatics support for pipeline development and tools

Xenium was delivered in late December, awaiting installation

7. Immunology Institute supporting integrative analysis of big 'omics and clinical data sets

Assembling the data "blocks" (containers) necessary for integrated analysis of 'omics and non-omics data



Alex Rosenberg



Jack Wimbish

Lopez de Maturana et al

<https://doi.org/10.3390/genes10030238>

Feature correlation matrices identify omics variables that are co-regulated in Long-COVID cohort samples



Alex Rosenberg

Cluster 1 Cytokines

IL-1a, IL-6, IL-13, IL-4, IL-12p40, sCD40L, IL-8, TNFb, IL-10, IL-15, IL-9, IL-5, IL-7

Cluster 2 Cytokines

FGF-2, VEGF, IL-12p70, IL-1b, IL-2, Flt-3L, Fractalkine, IL-1Ra, IFNg, IL-17A

Cluster 3 CMDS


Glucose, HbA1, BMI, CMDS

Cluster 4 Abs


C-NTD, C-Spike, C-RBD, S-Spike, S-RBD, H-Spike, O-Spike

Cluster 5 QOL

Cholesterol, LDL, HDL, QOL physical, QOL mental



- Cytokine (n = 35)
- Metabolism Labs (n = 11)
- Serum Reactivity (n = 8)
- Clinical (n = 4)
- PROMIS (n = 4)
- Metabolic Risk (n = 2)



Using 'Omics and clinical data to identify correlates of Long-COVID


QOL
Cluster 5

S.I. Level

$P_{LC} = 0.00000$

$P_{OB} = 0.74666$

$P_{INT} = 0.62233$




Cytokines
Cluster 1-2

G-CSF

$P_{LC} = 0.04105$

$P_{OB} = 0.60086$

$P_{INT} = 0.57943$




CMDS
Cluster 3

Diastolic

$P_{LC} = 0.00129$

$P_{OB} = 0.15789$

$P_{INT} = 0.37521$




Antibody
Cluster 4

C SP

$P_{LC} = 0.02363$

$P_{OB} = 0.25707$

$P_{INT} = 0.02797$




QOL
Cluster 5

LDL

$P_{LC} = 0.01625$


$P_{OB} = 0.92166$

$P_{INT} = 0.40957$



Long COVID
Obese

FY23 and FY24 Finances



FY23 Budgeting Buckets

FY23 Expenditures

- AMC21 Scholars
- Research Infrastructure (HDC, Immunophenotyping Core, Data Dictionary)
- Education and Outreach (PII, vaccine symposia, UIS)
- Capital Equipment (COMET; Xenium in FY24)
- Admin & Discretionary
- Pilot Project Funding (funds flow in FY24)
- Faculty Recruit/ Retain (funds flow FY24)
- Underspent by ~\$1M in FY22

CATEGORIES	BUDGETED	PAID OUT
AMC21 Scholars Program	150,000.00	125,000
Research Infrastructure	300,000.00	213,555
II Education and Outreach: PII, seminars, symposia, Workshops	90,000.00	22,732
Capital Equipment	200,000.00	125,000
II Administrative and Discretionary Support	285,000.00	102,306
Pilot Funding	150,000.00	
Lund Research Support (3123731)	200,000.00	200,000
TOTAL	\$1,375,000	\$788,593
Endowed Chair (direct to Endowed Chair acct) COMPLETE	500,000.00	500,000
Faculty Recruitment (no payouts yet)	500,000.00	-----

FY24 Budgeting Buckets

- On track to spend FY24 budget and significant amounts of CF from FY22 & FY23
- Pilot funding 2024 – 3 projects funded: Sudarshan/Norian; Raman; Feng
- Host SIS 2024 in BHM
- Vaccine Lecture and Symposium with Matthew Laurens (Univ MD)
- Faculty Recruitment and Retention - Funds requested for Erdmann Retention package (\$125,000 lump sum) and Goepfert Retention package (\$50,000/yr, 5 yrs)

CATEGORIES	BUDGETED	PAID OUT	PLANNED EXPENSES
AMC21 Scholars Program	150,000.00	170,000	
Research Infrastructure	300,000.00	46,736	546,051
II Education and Outreach: PII, seminars, symposia, Workshops	90,000.00	10,675	135,075
Capital Equipment (final year commitment)	250,000.00	80,280	5,000
II Administrative and Discretionary Support	285,000.00	53,039	234,442
Pilot Funding	150,000.00	107,000	100,000
Lund Research Support (3123731)	200,000.00	200,000	
	\$1,425,000	\$667,730	\$1,020,568
Faculty Recruitment/Retention	500,000.00		175,000


AMC21 Scholar Award Projected Budget Finances

FY22		
	\$75,000	FY19 AMC21 Scholars Year 2 – Bollar, Childers, Fisher, Hunter, Ziebro
	\$45,000	FY20 AMC21 Scholars Year 1 – Owiredu, Pierre, Pugh
	(\$30,000)	Co-Directors Year 3 (paid out from 3115431)
	\$120,000	
	\$30,000 total surplus	
FY23		
	\$40,000	FY20 AMC21 Scholars Year 2 – Owiredu (Prof Funds paid), Pierre, Pugh
	\$90,000	FY21 AMC21 Scholars Year 1 – Adamson, Barkley, Eli, Remiszewski, Song, Strickland
	(\$30,000)	Co-Directors Year 4 (to be paid out from 3115431)
	\$130,000	
	\$50,000 total surplus	
FY24		
	\$80,000	FY21 AMC21 Scholars Year 2 - Adamson, Barkley, Eli, Remiszewski (no stipend support), Song, Strickland
\$5,000/yr, 2 yrs Prof. funds	\$90,000	FY22 AMC21 Scholars Year 1 – Banna Siam, Brooks, Denslow, Echols, Patel, Sahlberg
\$10,00/yr, 2 yrs stipend support	(\$30,000)	Co-Directors Year 5 (to be paid out from 3115431)
	\$170,000	
	\$150,000	HSOM commitment
	\$30,000 total surplus	

FY25		
	\$90,000	FY22 AMC21 Scholars Year 2 – Banna Siam, Brooks, Denslow, Echols, Patel, Sahlberg
	\$45,000	FY23 AMC21 Scholars Year 1 – Ennis, Sanati, Suinn
	\$15,000	FY24 AMC21 Scholars cash award [Invites pending now]
	\$30,000	Co-Directors Year 6
	\$180,000	
	\$150,000	HSOM commitment
	\$0 total surplus	
FY26		
	\$45,000	FY23 AMC21 Scholars Year 2 – Ennis, Sanati, Suinn
	\$67,500	FY24 AMC21 Scholars Year 1 [Invites Pending Now]
	\$15,000	FY25 AMC21 Scholars cash award
	\$30,000	Co-Directors Year 7
	\$157,500	
	\$150,000	HSOM commitment
	\$7,500 total deficit	
FY27		
New HSOM commitment begins*	\$67,500	FY24 AMC21 Scholars Year 2 – [Invites Pending Now]
\$2,500 cash award in 1st semester	\$67,500	FY25 AMC21 Scholars Year 1
\$7,500/yr, 2 yrs stipend support	\$15,000	FY26 AMC21 Scholars cash award
\$3,750/yr, 2 yrs, Prof. funds	\$30,000	Co-Directors Year 8
	\$180,000	
	\$180,000	HSOM commitment*
	\$7,500 total deficit	

UAB THE UNIVERSITY OF
ALABAMA AT BIRMINGHAM.

FY24 Goals



UAB IMMUNOLOGY
INSTITUTE

The University of Alabama at Birmingham

2024 Priorities

1. Continue our initiatives in education and outreach
2. Host 2024 SIS in Birmingham in August
3. Establish an external advisory board
4. Initiate cluster hire for I-4ward and II relevant researchers – we are at a tipping point due to loss of significant cadre of wet lab researchers

Leaving/Left: Hubert Tse, Amy Weinmann, Beatriz Leon, Andre Ballesteros-Tato

Retired (or near retirement) or switched to non-research: Lou Justement, Janny Kabarowski, Noel Childers, John Kearney, Louise Chow, Jim Collawn, Chris Klug, Alex Szalai, Phil Smith, Harry Schroeder, Mike Saag, Jiri Mestecky, Lou Bridges



2024 Research Priorities

1. Introduce and publicize new cores (HDC, Immunophenotyping, Clinical Data bundles, single cell technologies) to UAB Researchers – *welcome suggestions on how best to do this*
2. Rollout and operationalize new capabilities/cores to users – *we are using individuals/labs as guinea pigs to test (what are the hiccups) before going live with cores*
3. Support informatic pipeline development for analyses of these complicated data sets
4. Establish new serology core
5. Begin new round of planning for future research infrastructure/core investments

Next up – II Antibody and Serology Core (Summer 2024)

Cytometric Bead Array services



Cytoflex

Simultaneous measurement of antigen-specific Abs (IgG, IgM, IgA).

Available arrays for β -Coronaviruses and Influenza antigens.

Flexible system configurable to 18 antigens in a single assay.

Luminex multiplexing services



MagPix

Measures up to 48 proteins in a 25 μ l sample (pg/ml sensitivity).

Up to 80 samples per assay (serum, plasma, sups, BAL, etc...).

>500 human analytes available, including cytokines/chemokines.

Ab binding kinetics services



Alto SPR

High-throughput, benchtop Surface Plasmon Resonance (SPR) system.

Handling of 2 μ l sample volumes.


Applications: Kinetics/affinity characterization, epitope mapping/binning, quantitation.

Operationalize II wet lab space

Proposed Immunology Core Space 1
5th Floor Shelby


To house two Immunology Institute Cores
(see next page for diagram)

1. Immunophenotyping Core. To include:
LN2 sample storage space and -80C storage
Sample prep space, robot, centrifuges,
biosafety cabinet and small equipment
2. Serology Core. To include:
ALTO SPR, Cytoflex CBA, Luminex
instruments, and sample prep space



4th Floor Shelby

Current U19 CCHI Core Space
Blue outline would like to trade
431D and 431E for 5th floor
space (see earlier diagram)



Future Research Priorities?

- ❖ Dirty Mouse Colony
- ❖ SEBLAB Immunologic Assay Core
- ❖ Human Lymph Node Biopsies, bone marrow aspirates, fat biopsies
- ❖ Human Tissue-derived Immune Cell Core
- ❖ Disease Cohort samples
- ❖ Vaccine and immunophenotyping for pre-clinical and clinical investigator and industry-initiated trials
- ❖ Microbiome initiatives (since loss of microbiome center)

